Mylan Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (36)

Latest Posts

About This Stock More About This Stock
Mylan Vs. Teva: Which Is The Better Generics Stock Ahead Of Earnings?
Article By: Swarup Gupta
Wednesday, May 10, 2017 4:10 AM EDT
Coming to the two generics producers, both Mylan and Teva are undervalued relative to their broader industry. However, Teva holds the edge here with a lower EV/EBITDA value of 7.58, compared to Mylan’s value of 8.12.
In this article: MYL, TEVA
Read
Pharma Stock Roundup: Merck Gets CRL For Label Expansion Effort, Roche Cancer Drug Tops
Article By: Arpita Dutt
Friday, April 14, 2017 12:00 PM EDT
It was a relatively slow week with key highlights including a complete response letter (CRL) for Merck’s label expansion efforts for its diabetes drugs and positive data on Roche’s lung cancer treatment.
In this article: AZN, JNJ, MRK, MYL, RHHBY, PFE, BMY
Read
T Minus One
Article By: Marvin R Clark
Thursday, January 19, 2017 11:18 PM EDT
The Dow Industrials erased its gains for 2017 as it fell for the fifth day in a row. The Russell 2000 also turned negative year to date.
In this article: AXP, CS, CVS, GS, HSBC, IBM, PBR, UBS, MYL
Read
Cempra Plunges To 52-Week Low, Shire Drug Label Expanded
Article By: Arpita Dutt
Friday, December 30, 2016 10:33 AM EDT
It was a relatively slow week for pharma stocks though a couple of companies suffered regulatory setbacks with the FDA issuing complete response letters (CRLs) for their regulatory applications.
In this article: AMPH, AZN, BMY, CEMP, MRK, MYL, SHPG
Read
Allergan Slides After Mylan Granted Request For Review Of Restasis Patent
Article By: The Fly
Thursday, December 8, 2016 6:13 PM EDT
Allergan shares are down 0.6% in late day trading, which is off the stock's earlier lows after news that Mylan Pharmaceuticals (MYL) filed a Petition requesting an inter partes review of a patent held by Allergan.
In this article: AGN, MYL
Read

PARTNER HEADLINES

Latest Tweets for $MYL

No tweets yet!